Abstract
Despite the effectiveness of nonsurgical standard treatments, the survival rates of high risk head and neck cancer patients still remains <50%. Therefore, new targeted therapeutic approaches are needed to improve the outcomes of patients with advanced high risk head and neck cancer. The majority of head and neck cancers harbor amplification or overexpression of EGFR, and over 50% have mutations in TP53. These alterations can impact the DNA damage response. ATR/Chk1 and ATM/Chk2 are the two main pathways that control cellular responses to DNA damage by engaging G2/M and G1/S cell cycle checkpoints. Chk1/2 inhibitors sensitize head and neck cancer tumor cells to DNA damaging agents, such as cisplatin, cetuximab, and ionizing radiation, and potentiate DNA damage in vitro and reduce tumor growth in vivo in head and neck models. The safety and efficacy of Chk1/2 inhibition in combination with first line chemotherapy and radiation is currently being evaluated in clinical trials for advanced and metastatic head and neck cancers. In this review we will highlight the emerging molecular therapeutics targeting DNA damage response and repair checkpoints and review the available data from pre-clinical studies and on-going clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Improving the Therapeutic Ratio in Head and Neck Cancer
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
